Quadrant Private Wealth Management LLC acquired a new position in Eli Lilly And Co (NYSE:LLY) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 1,959 shares of the company’s stock, valued at approximately $210,000.
Other hedge funds have also recently bought and sold shares of the company. Welch Group LLC acquired a new stake in Eli Lilly And Co in the 3rd quarter worth about $123,000. Zions Bancorporation acquired a new stake in Eli Lilly And Co in the 3rd quarter worth about $128,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in Eli Lilly And Co in the 2nd quarter worth about $114,000. Legacy Advisors LLC boosted its holdings in Eli Lilly And Co by 118.0% in the 2nd quarter. Legacy Advisors LLC now owns 1,354 shares of the company’s stock worth $116,000 after buying an additional 733 shares during the last quarter. Finally, Fort L.P. acquired a new stake in Eli Lilly And Co in the 2nd quarter worth about $121,000. Institutional investors own 76.17% of the company’s stock.
A number of research firms have weighed in on LLY. Cantor Fitzgerald set a $100.00 target price on shares of Eli Lilly And Co and gave the stock a “buy” rating in a research note on Tuesday, July 24th. Societe Generale set a $106.00 target price on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research note on Wednesday. ValuEngine lowered shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Tuesday. Credit Suisse Group set a $84.00 target price on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research note on Friday, July 13th. Finally, TheStreet raised shares of Eli Lilly And Co from a “c+” rating to a “b+” rating in a research note on Tuesday. Nine research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $111.19.
Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Tuesday, November 6th. The company reported $1.39 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.35 by $0.04. The firm had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. Eli Lilly And Co had a net margin of 1.85% and a return on equity of 42.84%. The business’s revenue for the quarter was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.05 EPS. Sell-side analysts forecast that Eli Lilly And Co will post 5.57 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, December 10th. Stockholders of record on Thursday, November 15th will be given a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a dividend yield of 2.01%. The ex-dividend date of this dividend is Wednesday, November 14th. Eli Lilly And Co’s payout ratio is presently 52.57%.
In other news, major shareholder Eli & Co Lilly sold 4,531 shares of Eli Lilly And Co stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $14.33, for a total transaction of $64,929.23. Following the sale, the insider now owns 3,934,137 shares of the company’s stock, valued at approximately $56,376,183.21. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 151,793 shares of Eli Lilly And Co stock in a transaction that occurred on Wednesday, August 15th. The shares were sold at an average price of $103.23, for a total transaction of $15,669,591.39. Following the sale, the insider now directly owns 120,555,804 shares in the company, valued at approximately $12,444,975,646.92. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,881,684 shares of company stock worth $133,274,076. Corporate insiders own 0.11% of the company’s stock.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: Market Capitalization
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.